

Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis

Date Published: Tuesday, 2 Jan 2024

DETAILED NEWS

- ↪ Gannex Pharma Co., Ltd. announced a positive interim results from the 52-week Phase II clinical trial of thyroid hormone receptor (THR) agonist ASC41 tablet for treatment of patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).
- ↪ ASC41 is liver-targeting and highly THR-selective.
- ↪ Once-daily ASC41 tablet was developed by using Ascletis proprietary formulation technology.
- ↪ The patent of ASC41 tablet formulation has been granted in the U.S. Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients receiving 12-week treatment of ASC41 tablet

KEY HIGHLIGHTS

- ↪ - Gannex Pharma Co., Ltd. has reported positive interim results from a 52-week Phase II clinical trial of its thyroid hormone receptor (THR) agonist ASC41 tablet.
- ↪ - The ASC41 tablet is designed for the treatment of patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) and is known for its liver-targeting and high THR-selectivity.
- ↪ - The ASC41 tablet was developed using Ascletis' proprietary formulation technology and its patent has been approved in the United States.
- ↪ - During the trial, patients with biopsy-confirmed NASH received a once-daily dose of the ASC41 tablet.
- ↪ - A significant improvement was observed, with up to a 68.2% mean relative reduction in liver fat content from the baseline in these patients after a 12-week treatment period with the ASC41 tablet.

